Boston Scientific (NYSE:BSX) Shares Unloaded Rep. Kevin Hern

Representative Kevin Hern (R-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on November 16th, the Representative disclosed that they had sold between $15,001 and $50,000 in Boston Scientific stock on October 28th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 10/28/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 10/28/2025.
• Sold $1,001 – $15,000 in shares of O’Reilly Automotive (NASDAQ:ORLY) on 10/28/2025.
• Sold $15,001 – $50,000 in shares of Seagate Technology (NASDAQ:STX) on 10/28/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 10/28/2025.
• Sold $100,001 – $250,000 in shares of Accenture (NYSE:ACN) on 10/27/2025.
• Sold $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 10/23/2025.
• Sold $100,001 – $250,000 in shares of McDonald’s (NYSE:MCD) on 10/23/2025.
• Sold $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 10/6/2025.
• Sold $15,001 – $50,000 in shares of Masimo (NASDAQ:MASI) on 9/26/2025.

Boston Scientific Price Performance

Shares of BSX stock traded up $0.17 during trading hours on Friday, hitting $96.77. 13,388,268 shares of the company’s stock were exchanged, compared to its average volume of 8,043,485. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The stock has a market cap of $143.46 billion, a price-to-earnings ratio of 51.75, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock’s 50-day moving average is $98.97 and its 200-day moving average is $102.36.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 175,782 shares of company stock worth $17,742,314. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after buying an additional 1,115,337 shares during the last quarter. State Street Corp raised its position in shares of Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the period. Geode Capital Management LLC raised its position in shares of Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after acquiring an additional 622,602 shares during the period. Norges Bank bought a new position in Boston Scientific during the 2nd quarter worth approximately $2,089,937,000. Finally, Invesco Ltd. grew its holdings in Boston Scientific by 0.7% during the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after purchasing an additional 111,826 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on BSX. Truist Financial increased their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Canaccord Genuity Group reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research report on Thursday, October 23rd. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. UBS Group upped their price target on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, Robert W. Baird lifted their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $123.77.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.